KevinMD June 20, 2022
Why does one person respond favorably to lung cancer treatment while another does not?
The answer lies in their DNA.
Just 20 years ago, lung cancer was broadly categorized into two groups: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Relatively recently, the treatment of NSCLC shifted from chemotherapy as a single treatment option to treatment with precision medicine, which is positively impacting survival rates.
Within the past ten years, researchers and clinicians started to understand biological differences between the two most common subtypes of NSCLC (adenocarcinoma and squamous cell carcinoma), which provided insight into why certain patients had greater success with treatment.
A breakthrough occurred when we discovered specific ‘driver’ gene mutations within the tumor, realized...
Today's Sponsors
Today's Sponsor